These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Temozolomide in malignant gliomas: current use and future targets.
    Author: Villano JL, Seery TE, Bressler LR.
    Journal: Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728.
    Abstract:
    Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.
    [Abstract] [Full Text] [Related] [New Search]